Dominik Schumacher, Tubulis 🇩🇪 | Founder-led ADC Biotech ⭐️ | E19
Listen now
Description
We’re in Munich 🇩🇪 with a “true” biotech founder, Dominik Schumacher of Tubulis. Not many biotechs in Europe are led by a founder PhD under 40 and have scaled to raising over 100M. I know only two, one is Thomas at Owkin and the other one is Dominik at Tubulis. We talked about building a champion ADC biotech, the super hot ADC sphere, and the difference between luck and success. 🔗 LINKS MENTIONED - https://curie.bio/ - https://curie.bio - Tubulis Closes Upsized €128 Million Series B2 to Accelerate Clinical Development of Solid Tumor-Focused ADC Pipeline - https://tubulis.com/news/tubulis-closes-upsized-e128-million-series-b2-to-accelerate-clinical-development-of-solid-tumor-focused-adc-pipeline/ - BioSpace - Next wave of ADCs - https://www.biospace.com/article/the-next-wave-of-adcs-could-treat-evasive-solid-tumors-/ - BMS axes Eisai ADC pact 3 years after paying $650M for would-be Elahere rival - https://www.fiercebiotech.com/biotech/bms-axes-eisai-adc-pact-3-years-after-paying-650m-would-be-elahere-rival - Merck’s ADC Pact With Daiichi Hits Regulatory Setback in FDA Rejection - https://www.biospace.com/article/merck-s-adc-pact-with-daiichi-hits-regulatory-setback-with-fda-rejection/ - ADC Space is too crowded? - https://drive.google.com/file/d/1oA23bidvd2G-z2lnAkPLAMZgl1RXLtr9/view?usp=sharing - Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio ($1.8B cash) - https://ir.genmab.com/news-releases/news-release-details/genmab-broaden-and-strengthen-oncology-portfolio-acquisition - BIO-Europe Spring 2019: Newcomer Tubulis tackles ADC technology shortcomings - https://www.youtube.com/watch?v=wwr5KMypBHs - Top 20 Healthcare Specialist Investors - https://drive.google.com/file/d/1r4IwIKvuVUYQaqCZnpm4DtEYyy3LIT7h/view?usp=sharing 📜 TRANSCRIPT Read the full transcript here: https://flot.bio/episode/dominik-schumacher-tubulis/ 💸 DONATE We welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme ⭐️ SPONSORSHIP Ready to amplify your brand to influential leaders in biotech and biopharma? Contact [email protected] and unlock sponsorship opportunities in our podcasts! 🫶 FOLLOW US - Newsletter: http://eepurl.com/h_fnmH - LinkedIn: https://www.linkedin.com/company/flot-bio/ - X (Twitter): https://x.com/FlotBio 🙏 LIKE/FOLLOW/REVIEW Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below. 🎙️ ABOUT FLOT.BIO Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 15k monthly views. Free. ⏰ TIMESTAMPS [00:00:00] Intro [00:01:44] Entrepreneurial biotech family [00:08:46] Market validation [00:14:32] Why Munich [00:17:33] Founder-led biotechs [00:25:20] Balancing 3 kids [00:29:31] Tubulis & ADCs [00:38:25] ADC space is crowded [00:46:12] Deep Track Capital [00:48:17] Vision for Tubulis [00:52:59] ADC space is hot [00:58:03] Chinese biotech [01:02:53] Luck vs success
More Episodes
We’re online with Adrian Rawcliffe, the CEO of Adaptimmune, the TCR cell therapy company behind the first engineered cell therapy for solid tumors that was approved for a rare form of sarcoma. We talked about Tecelra's commercial rollout. We also talked about what's next in cell therapy, and...
Published 10/28/24
Published 10/28/24